T1	PROC 58 72	ensayo clínico
#1	AnnotatorNotes T1	C0008976; Clinical Trials; Research Activity
T2	Spec_cue 99 104	puede
T3	CHEM 114 136	fármaco hipolipemiante
T4	CHEM 154 167	pitavastatina
#2	AnnotatorNotes T4	C1101838; pitavastatin; Organic Chemical · Pharmacologic Substance
T5	LIVB 171 180	pacientes
#3	AnnotatorNotes T5	C0030705; Patients; Patient or Disabled Group
T6	DISO 185 203	cáncer de próstata
#4	AnnotatorNotes T6	C0376358; Malignant neoplasm of prostate; Neoplastic Process
T7	PROC 232 240	tratados
T8	CHEM 256 270	antiandrógenos
#5	AnnotatorNotes T8	C0002842; Androgen Antagonists; Pharmacologic Substance
T9	CHEM 311 324	pitavastatina
#6	AnnotatorNotes T9	C1101838; pitavastatin; Organic Chemical · Pharmacologic Substance
T10	LIVB 328 337	pacientes
#7	AnnotatorNotes T10	C0030705; Patients; Patient or Disabled Group
T11	DISO 342 360	cáncer de próstata
#8	AnnotatorNotes T11	C0376358; Malignant neoplasm of prostate; Neoplastic Process
T12	PROC 361 369	tratados
T13	PROC 374 393	terapia androgénica
T14	PROC 415 443	ensayo clínico multicéntrico
T15	CHEM 483 490	fármaco
#9	AnnotatorNotes T15	C0013227; Pharmaceutical Preparations; Pharmacologic Substance
T16	CHEM 514 527	pitavastatina
#10	AnnotatorNotes T16	C1101838; pitavastatin; Organic Chemical · Pharmacologic Substance
T17	LIVB 555 564	pacientes
#11	AnnotatorNotes T17	C0030705; Patients; Patient or Disabled Group
T18	DISO 569 587	cancer de próstata
#12	AnnotatorNotes T18	C0376358; Malignant neoplasm of prostate; Neoplastic Process
T19	PROC 702 744	ensayo clínico, randomizado y simple ciego
T20	CHEM 818 827	estatinas
#13	AnnotatorNotes T20	C0075191; statine; Amino Acid, Peptide, or Protein | C0360714; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Organic Chemical · Pharmacologic Substance
T21	LIVB 831 840	pacientes
#14	AnnotatorNotes T21	C0030705; Patients; Patient or Disabled Group
T22	DISO 845 863	cáncer de próstata
#15	AnnotatorNotes T22	C0376358; Malignant neoplasm of prostate; Neoplastic Process
T23	PROC 881 889	tratados
T24	CHEM 894 898	ARTA
T25	CHEM 900 912	enzalutamida
#16	AnnotatorNotes T25	C3496793; enzalutamide; Organic Chemical · Pharmacologic Substance
T26	CHEM 914 925	apalutamida
#17	AnnotatorNotes T26	C4551002; Erleada; Organic Chemical · Pharmacologic Substance
T27	CHEM 927 939	darolutamida
T28	CHEM 942 953	abiraterona
#18	AnnotatorNotes T28	C0754011; abiraterone; Organic Chemical · Pharmacologic Substance
T29	LIVB 1005 1023	grupo experimental
#19	AnnotatorNotes T29	C1320290; Clinical trial group; Patient or Disabled Group
T30	DISO 1076 1086	metástasis
#20	AnnotatorNotes T30	C0027627; Neoplasm Metastasis; Neoplastic Process | C2939419; Secondary Neoplasm; Neoplastic Process
T31	LIVB 1168 1177	Pacientes
#21	AnnotatorNotes T31	C0030705; Patients; Patient or Disabled Group
T32	PROC 1182 1205	diagnóstico histológico
T33	DISO 1209 1227	cáncer de próstata
#22	AnnotatorNotes T33	C0376358; Malignant neoplasm of prostate; Neoplastic Process
T34	LIVB 1357 1366	Pacientes
#23	AnnotatorNotes T34	C0030705; Patients; Patient or Disabled Group
T35	DISO 1371 1418	cáncer de próstata metastásico hormonosensibles
T36	DISO 1420 1425	CPHSm
T37	Neg_cue 1432 1434	no
T38	CHEM 1467 1486	superantiandrógenos
T39	Negated 1467 1486	superantiandrógenos
T40	Neg_cue 1487 1489	ni
T41	PROC 1490 1503	quimioterapia
#24	AnnotatorNotes T41	C0013216; Pharmacotherapy; Therapeutic or Preventive Procedure | C0392920; Chemotherapy Regimen; Therapeutic or Preventive Procedure | C3665472; Chemotherapy; Therapeutic or Preventive Procedure
T42	Negated 1490 1503	quimioterapia
T43	LIVB 1510 1519	Pacientes
#25	AnnotatorNotes T43	C0030705; Patients; Patient or Disabled Group
T44	DISO 1524 1554	cáncer de próstata metastásico
#26	AnnotatorNotes T44	C0936223; Metastatic Prostate Carcinoma; Neoplastic Process
T45	PROC 1571 1581	castración
#27	AnnotatorNotes T45	C0007344; Castration; Therapeutic or Preventive Procedure
T46	DISO 1583 1588	CPRCm
#28	AnnotatorNotes T46	C4721208; Metastatic castration-resistant prostate cancer; Neoplastic Process
T47	Neg_cue 1595 1597	no
T48	CHEM 1630 1649	superantiandrógenos
T49	Negated 1630 1649	superantiandrógenos
T50	Neg_cue 1650 1652	ni
T51	PROC 1653 1666	quimioterapia
#29	AnnotatorNotes T51	C0013216; Pharmacotherapy; Therapeutic or Preventive Procedure | C0392920; Chemotherapy Regimen; Therapeutic or Preventive Procedure | C3665472; Chemotherapy; Therapeutic or Preventive Procedure
T52	Negated 1653 1666	quimioterapia
T53	DISO 1697 1715	cáncer de próstata
#30	AnnotatorNotes T53	C0376358; Malignant neoplasm of prostate; Neoplastic Process
T54	PROC 1732 1742	castración
#31	AnnotatorNotes T54	C0007344; Castration; Therapeutic or Preventive Procedure
T55	PROC 1783 1786	PSA
#32	AnnotatorNotes T55	C0201544; Prostate specific antigen measurement; Laboratory Procedure
T56	Duration 1802 1821	al menos una semana
T57	PROC 1910 1913	PSA
#33	AnnotatorNotes T57	C0201544; Prostate specific antigen measurement; Laboratory Procedure
T58	PROC 1934 1957	Niveles de testosterona
#34	AnnotatorNotes T58	C0523912; Testosterone measurement; Laboratory Procedure
T59	DISO 2010 2024	lesiones óseas
#35	AnnotatorNotes T59	C0238792; Bone lesion; Disease or Syndrome
T60	PROC 2032 2048	gammagrafía ósea
#36	AnnotatorNotes T60	C0203668; Radioisotope scan of bone; Diagnostic Procedure | C3889015; Bone scintigraphy; Diagnostic Procedure
T61	DISO 2065 2092	lesiones de tejidos blandos
#37	AnnotatorNotes T61	C0410013; Soft tissue lesion; Pathologic Function
T62	LIVB 2125 2134	Pacientes
#38	AnnotatorNotes T62	C0030705; Patients; Patient or Disabled Group
T63	DISO 2139 2157	cáncer de próstata
#39	AnnotatorNotes T63	C0376358; Malignant neoplasm of prostate; Neoplastic Process
T64	PROC 2174 2184	castración
#40	AnnotatorNotes T64	C0007344; Castration; Therapeutic or Preventive Procedure
T65	Neg_cue 2185 2187	no
T66	DISO 2188 2200	metastásicos
#41	AnnotatorNotes T66	C4255448; Metastasis; Pathologic Function
T67	Negated 2188 2200	metastásicos
T68	DISO 2202 2208	CRPCnm
T69	PROC 2253 2256	PSA
#42	AnnotatorNotes T69	C0201544; Prostate specific antigen measurement; Laboratory Procedure
T70	Duration 2257 2266	< 6 meses
T71	LIVB 2277 2286	pacientes
#43	AnnotatorNotes T71	C0030705; Patients; Patient or Disabled Group
T72	DISO 2291 2294	CaP
#44	AnnotatorNotes T72	C0013274; Patent ductus arteriosus; Congenital Abnormality | C0033036; Atrial Premature Complexes; Disease or Syndrome
T73	PROC 2308 2319	tratamiento
#45	AnnotatorNotes T73	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T74	CHEM 2340 2348	fármacos
#46	AnnotatorNotes T74	C0013227; Pharmaceutical Preparations; Pharmacologic Substance
T75	DISO 2365 2375	enfermedad
#47	AnnotatorNotes T75	C0012634; Disease; Disease or Syndrome | C0221423; Illness (finding); Sign or Symptom
T76	CHEM 2379 2390	Abiraterona
#48	AnnotatorNotes T76	C0754011; abiraterone; Organic Chemical · Pharmacologic Substance
T77	CHEM 2394 2406	Enzalutamida
#49	AnnotatorNotes T77	C3496793; enzalutamide; Organic Chemical · Pharmacologic Substance
T78	CHEM 2410 2421	Apalutamida
#50	AnnotatorNotes T78	C4551002; Erleada; Organic Chemical · Pharmacologic Substance
T79	CHEM 2425 2437	Darolutamida
T80	CHEM 2442 2449	Fármaco
#51	AnnotatorNotes T80	C0013227; Pharmaceutical Preparations; Pharmacologic Substance
T81	CHEM 2485 2498	pitavastatina
#52	AnnotatorNotes T81	C1101838; pitavastatin; Organic Chemical · Pharmacologic Substance
T82	Dose 2499 2503	2 mg
T83	LIVB 2536 2545	Pacientes
#53	AnnotatorNotes T83	C0030705; Patients; Patient or Disabled Group
T84	DISO 2550 2564	hiperlipidemia
#54	AnnotatorNotes T84	C0020473; Hyperlipidemia; Disease or Syndrome | C0020476; Hyperlipoproteinemias; Disease or Syndrome
T85	PROC 2583 2594	diagnóstico
#55	AnnotatorNotes T85	C0011900; Diagnosis; Diagnostic Procedure
T86	PROC 2611 2636	tratamiento farmacológico
#56	AnnotatorNotes T86	C0013216; Pharmacotherapy; Therapeutic or Preventive Procedure
T87	Neg_cue 2611 2636	tratamiento farmacológico
T88	LIVB 2642 2651	Pacientes
#57	AnnotatorNotes T88	C0030705; Patients; Patient or Disabled Group
T89	PROC 2656 2680	niveles de transaminasas
T90	LIVB 2725 2734	Pacientes
#58	AnnotatorNotes T90	C0030705; Patients; Patient or Disabled Group
T91	LIVB 2812 2821	Pacientes
#59	AnnotatorNotes T91	C0030705; Patients; Patient or Disabled Group
T92	Neg_cue 2826 2834	rechacen
T93	Neg_cue 2862 2864	no
T94	PROC 2875 2899	consentimiento informado
#60	AnnotatorNotes T94	C0567423; Informed consent for procedure; Therapeutic or Preventive Procedure
T95	Negated 2875 2899	consentimiento informado
T96	Spec_cue 616 621	puede
T97	Negated 2202 2208	CRPCnm
T98	PROC 2852 2859	estudio
T99	Negated 2852 2859	estudio
T100	Speculated 114 136	fármaco hipolipemiante
T101	Speculated 154 167	pitavastatina
T102	DISO 634 661	progresión de la enfermedad
T103	Speculated 634 661	progresión de la enfermedad
T104	Neg_cue 2603 2605	no
T105	Observation 85 94	beneficio
T106	Quantifier_or_Qualifier 204 212	avanzado
T107	Observation 540 551	beneficioso
T108	Quantifier_or_Qualifier 588 596	avanzado
T109	CONC 622 630	retrasar
T110	Observation 634 644	progresión
T111	Observation 793 810	beneficio clínico
T112	CONC 1039 1046	aumento
T113	CONC 1053 1066	supervivencia
T114	Observation 1118 1140	progresión radiológica
T115	Observation 1261 1278	estadios clínicos
T116	Observation 1555 1581	resistente a la castración
T117	Observation 1716 1742	resistente a la castración
T118	Quantifier_or_Qualifier 1750 1766	Tres elevaciones
T119	Quantifier_or_Qualifier 1767 1779	consecutivas
T120	Result_or_Value 1847 1850	50%
T121	Result_or_Value 1860 1865	nadir
T122	Result_or_Value 1914 1931	mayor de 2 ng/ml.
T123	Result_or_Value 1958 1993	inferiores a 50 ng/dl ó 1.7 nmol/l.
T124	Observation 1996 2006	Progresión
T125	Quantifier_or_Qualifier 2025 2028	≥ 2
T126	Observation 2051 2061	progresión
T127	CONC 2103 2112	criterios
T128	CONC 2113 2119	RECIST
T129	Observation 2158 2184	resistente a la castración
T130	Quantifier_or_Qualifier 2188 2200	metastásicos
T131	Observation 2215 2226	alto riesgo
T132	CONC 2228 2256	tiempo de duplicación de PSA
T133	Quantifier_or_Qualifier 2349 2356	activos
T134	Result_or_Value 2681 2719	dos veces por encima del valor normal.
T135	CONC 2764 2775	información
T136	Observation 2835 2859	formar parte del estudio
T137	Patient 171 180	pacientes
T138	Patient 328 337	pacientes
T139	Patient 555 564	pacientes
T140	Patient 831 840	pacientes
T141	Patient 1005 1023	grupo experimental
T142	Patient 1168 1177	Pacientes
T143	Patient 1357 1366	Pacientes
T144	History_of 1450 1455	línea
T145	History_of 1467 1486	superantiandrógenos
T146	History_of 1490 1503	quimioterapia
T147	Patient 1510 1519	Pacientes
T148	History_of 1613 1618	línea
T149	History_of 1630 1649	superantiandrógenos
T150	History_of 1653 1666	quimioterapia
T151	Patient 2125 2134	Pacientes
T152	Patient 2277 2286	pacientes
T153	Patient 2536 2545	Pacientes
T154	Patient 2642 2651	Pacientes
T155	Patient 2725 2734	Pacientes
T156	Patient 2812 2821	Pacientes
